Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?

Motley Fool12-21 18:26

Merck just closed a deal to develop a weight-loss drug. The market appears to think Viking Therapeutics is threatened by that data. There's little reason to write off Viking here. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493231769?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801604%2Fchemist-team-looking-beaker-of-green-chemical.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-12-21 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493231769","market":"fut","top_or_hot":-1,"title":"Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?","media":"Motley Fool","content":"<div>\n<p>Merck just closed a deal to develop a weight-loss drug.\n\n\n\n\n\n\n\nThe market appears to think Viking Therapeutics is threatened by that data.\n\n\n\n\n\n\n\nThere's little reason to write off Viking here. \n\nThe ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/12/21/down-18-in-1-day-is-viking-therapeutics-stock-in-t/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDown 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-21 18:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/12/21/down-18-in-1-day-is-viking-therapeutics-stock-in-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck just closed a deal to develop a weight-loss drug.\n\n\n\n\n\n\n\nThe market appears to think Viking Therapeutics is threatened by that data.\n\n\n\n\n\n\n\nThere's little reason to write off Viking here. \n\nThe ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/12/21/down-18-in-1-day-is-viking-therapeutics-stock-in-t/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://www.fool.com/investing/2024/12/21/down-18-in-1-day-is-viking-therapeutics-stock-in-t/","article_id":"2493231769","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801604%2Fchemist-team-looking-beaker-of-green-chemical.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493231769","pubTimestamp":1734776760,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Merck just closed a deal to develop a weight-loss drug.The market appears to think Viking Therapeutics is threatened by that data.There's little reason to write off Viking here.The weight-loss biotech Viking Therapeutics  saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck .Given that Viking doesn't yet have any products approved for sale, is this the start of the end, or just a rough bump in the road?","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4534":"瑞士信贷持仓","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4139":"生物科技","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","BK4559":"巴菲特持仓","MRK":"默沙东","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4516":"特朗普概念","VKTX":"Viking Therapeutics, Inc.","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC"},"translate_title":"1天跌18%，Viking Therapeutics股票因默沙东陷入困境？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1,"MRK":1},"content_text":"Merck just closed a deal to develop a weight-loss drug.\n\n\n\n\n\n\n\nThe market appears to think Viking Therapeutics is threatened by that data.\n\n\n\n\n\n\n\nThere's little reason to write off Viking here. \n\nThe weight-loss biotech Viking Therapeutics (VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (MRK -1.48%).Given that Viking doesn't yet have any products approved for sale, is this the start of the end, or just a rough bump in the road?The market's fears are overblown, but not ungroundedFirst, let's get to the bottom of what Merck did to provoke Viking's stock into tumbling so much and so quickly.Merck just signed a licensing deal with a biotech based in China so that it could develop and potentially commercialize that company's oral weight-loss candidate, HS-10535. It paid $112 million in cash. Merck also agreed to pay as much as $1.9 billion in milestone payments, and it's also liable for royalties on sales if the program is ever approved for sale.At the moment, HS-10535 is in preclinical testing; Merck would make a deal to license the candidate only if the preclinical performance data suggested a very strong chance at meeting the safety and efficacy requirements of clinical trials in human subjects.Therefore, it is highly likely that HS-10535 will be advanced into clinical trials as soon as the business can get permission from regulators to do so.Right off the bat, it's pretty clear why investors dumped Viking's stock. The arrival of a new major competitor in the burgeoning anti-obesity drug market doesn't bode well for smaller players that haven't established themselves as self-sustaining companies yet.Viking's $930.4 million in cash, equivalents, and short-term investments will keep the lights on for quite some time at its current rate of spending, but Merck's ability to generate earnings from sales of its many commercialized medicines means that it can probably persist in the face of clinical-stage failures for far longer if it chooses to do so.The biggest company will also doubtlessly be able to tap far more formidable resources devoted to manufacturing, marketing, distribution, and other crucial commercialization activities, not to mention having far more experience with execution.Viking's weight-loss drug, VK2735, is being tested in both an injectable and an oral format, but the oral format is only in the planning stages of its upcoming phase 2 trials, whereas the injected format is soon to advance into phase 3 after a successful phase 2.Assuming Merck advances quickly into the clinic, its candidate will thus be a little bit more than one entire phase behind the oral formulation of VK2735, which would be its most direct competitor if both medicines were eventually approved for sale.All told, Viking's oral candidate might have a year or so on the market before needing to compete with Merck's option. That should be enough time for it to capture a decent market share, considering that the clinical data so far indicates that VK2735 will likely be more effective at causing weight loss than competing products made by Eli Lilly and Novo Nordisk. As the market for anti-obesity drugs is not yet saturated and is still rising, the presence of those competitors is, all things considered, not very daunting.For a biotech with zero revenue, that one year on the market would probably be enough to make VK2735 a blockbuster drug, earning more than $1 billion in sales within 12 months and delivering a massive amount of growth to shareholders in the process.And even if Viking's oral formulation does eventually have its market share eroded by a drug from Merck, the injectable formulation of VK2735 could reach the market even sooner if its final trials go as planned.So there is little reason to think that it's game over for Viking, as it still has a clear opportunity to flourish, even if it now has a powerful adversary breathing down its neck.This is a good time to buy the dipIn light of the above, Viking Therapeutics is not itself in trouble right now. The market's reaction to Merck's announcement assumes the very best outcome for its upcoming clinical trials for HS-10535, and it also assumes lackluster performance from VK2735.Thus, if you're looking for an opportunity to buy the dip with Viking Therapeutics, now is a favorable time to do so. Within a few quarters, it will be reporting preliminary data from its mid- and late-stage clinical trials once more, building up enthusiasm for its shares, assuming the readouts are positive. Hitting a clinical bump in the road won't be the end of the company, either -- and besides, Merck could be the one hitting a bump soon enough.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493231769"}